| Musto, Pellegrino |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Active, not recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 100 | Europe | Venetoclax and Decitabine | Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen | Acute Myeloid Leukemia | 02/23 | 06/25 | | |
| Recruiting | 2 | 50 | Europe | Elranatamab | Stichting European Myeloma Network, Pfizer | Smoldering Multiple Myeloma | 07/27 | 07/31 | | |
| Recruiting | 2 | 41 | Europe | RVU120 (SEL120) | GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group | Low Risk Myelodysplastic Syndromes | 05/26 | 05/27 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
| Recruiting | N/A | 10000 | Europe | | Fondazione Italiana Sindromi Mielodisplastiche-ETS | Myelodysplastic-Myeloproliferative Diseases | 06/16 | 05/32 | | |
| Recruiting | N/A | 1068 | Europe, RoW | all-trans retinoic acid (ATRA) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Leukemia | 12/20 | 12/20 | | |
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia |
|
|
| Active, not recruiting | N/A | 75 | Europe | Immunogenic profile | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context |
|
|
| Recruiting | N/A | 50 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Primary Mediastinal B Cell Lymphoma | 12/25 | 12/25 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
| Completed | N/A | 215 | Europe | Luspatercept | Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas | Myeloid Dysplasia | 12/22 | 01/23 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
| Recruiting | N/A | 760 | Europe | no intervention | Fondazione IRCCS Policlinico San Matteo di Pavia | AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | 05/25 | 05/25 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
NCT04587856: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients |
|
|
| Recruiting | N/A | 38 | Europe | bone marrow withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | Myelodysplastic Syndromes | 03/25 | 03/25 | | |
| Recruiting | N/A | 1900 | Europe | Observation | Fondazione EMN Italy Onlus | Multiple Myeloma | 03/24 | 03/24 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
NCT05553873: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study. |
|
|
| Recruiting | N/A | 500 | Europe | | University of Milano Bicocca | Myeloproliferative Disease, Inflammatory Markers | 12/26 | 12/26 | | |
